Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials
The effective treatment modalities for severe coronavirus disease 2019 (COVID-19) are needed. As the primary cause of mortality is a hyperinflammatory state, the interleukin-6 antagonist tocilizumab has been used in multiple clinical studies. We conducted this systematic review and meta-analysis to...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2022-02-01
|
| Series: | Monaldi Archives for Chest Disease |
| Subjects: | |
| Online Access: | https://www.monaldi-archives.org/index.php/macd/article/view/2136 |
| _version_ | 1818297986355036160 |
|---|---|
| author | Tarun Krishna Boppana Saurabh Mittal Karan Madan Anant Mohan Vijay Hadda Randeep Guleria |
| author_facet | Tarun Krishna Boppana Saurabh Mittal Karan Madan Anant Mohan Vijay Hadda Randeep Guleria |
| author_sort | Tarun Krishna Boppana |
| collection | DOAJ |
| description | The effective treatment modalities for severe coronavirus disease 2019 (COVID-19) are needed. As the primary cause of mortality is a hyperinflammatory state, the interleukin-6 antagonist tocilizumab has been used in multiple clinical studies. We conducted this systematic review and meta-analysis to estimate the effectiveness of tocilizumab in reduction of mortality due to COVID-19. A systematic search of the Pubmed and Embase databases was performed to extract randomized controlled trials (RCTs) regarding the use of tocilizumab therapy for COVID-19. An overall pooled mortality analysis was performed, and odds ratios were reported. Cochrane risk of bias assessment tool was used to assess the risk of bias. Heterogeneity was assessed using the I2 statistic. Nine RCTs, including 6489 patients, were selected for meta-analysis. Seven trials reported 28-day mortality, and one trial each reported 21-day and 30-day mortality. There were 846 deaths among 3358 participants in the steroid group while 943 deaths among 3131 patients randomized to the control group (random-effects odds ratio 0.87, 95% confidence interval 0.73-1.03, p=0.11). There was some heterogeneity among the trials as the I2 value was 15%, with a p-value of 0.31. There was a reduction in the need for ICU admission in the tocilizumab group. A higher risk of secondary infections was noted in the tocilizumab group (fixed-effects odds ratio 0.72, 95% confidence interval 0.55-0.95, p=0.02). This meta-analysis of RCTs demonstrated that the use of tocilizumab was not associated with a reduction in all-cause mortality in patients with COVID-19 and had higher odds of secondary infections. |
| first_indexed | 2024-12-13T04:28:09Z |
| format | Article |
| id | doaj.art-a92fc8a6e6834f16b104751d4100e527 |
| institution | Directory Open Access Journal |
| issn | 1122-0643 2532-5264 |
| language | English |
| last_indexed | 2024-12-13T04:28:09Z |
| publishDate | 2022-02-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Monaldi Archives for Chest Disease |
| spelling | doaj.art-a92fc8a6e6834f16b104751d4100e5272022-12-21T23:59:39ZengPAGEPress PublicationsMonaldi Archives for Chest Disease1122-06432532-52642022-02-0110.4081/monaldi.2022.2136Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trialsTarun Krishna Boppana0Saurabh Mittal1Karan Madan2Anant Mohan3Vijay Hadda4Randeep Guleria5Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New DelhiDepartment of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New DelhiDepartment of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New DelhiDepartment of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New DelhiDepartment of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New DelhiDepartment of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New DelhiThe effective treatment modalities for severe coronavirus disease 2019 (COVID-19) are needed. As the primary cause of mortality is a hyperinflammatory state, the interleukin-6 antagonist tocilizumab has been used in multiple clinical studies. We conducted this systematic review and meta-analysis to estimate the effectiveness of tocilizumab in reduction of mortality due to COVID-19. A systematic search of the Pubmed and Embase databases was performed to extract randomized controlled trials (RCTs) regarding the use of tocilizumab therapy for COVID-19. An overall pooled mortality analysis was performed, and odds ratios were reported. Cochrane risk of bias assessment tool was used to assess the risk of bias. Heterogeneity was assessed using the I2 statistic. Nine RCTs, including 6489 patients, were selected for meta-analysis. Seven trials reported 28-day mortality, and one trial each reported 21-day and 30-day mortality. There were 846 deaths among 3358 participants in the steroid group while 943 deaths among 3131 patients randomized to the control group (random-effects odds ratio 0.87, 95% confidence interval 0.73-1.03, p=0.11). There was some heterogeneity among the trials as the I2 value was 15%, with a p-value of 0.31. There was a reduction in the need for ICU admission in the tocilizumab group. A higher risk of secondary infections was noted in the tocilizumab group (fixed-effects odds ratio 0.72, 95% confidence interval 0.55-0.95, p=0.02). This meta-analysis of RCTs demonstrated that the use of tocilizumab was not associated with a reduction in all-cause mortality in patients with COVID-19 and had higher odds of secondary infections.https://www.monaldi-archives.org/index.php/macd/article/view/2136TocilizumabCOVID-19meta-analysisinterleukin 6IL-6 inhibitorSARS CoV-2 |
| spellingShingle | Tarun Krishna Boppana Saurabh Mittal Karan Madan Anant Mohan Vijay Hadda Randeep Guleria Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials Monaldi Archives for Chest Disease Tocilizumab COVID-19 meta-analysis interleukin 6 IL-6 inhibitor SARS CoV-2 |
| title | Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials |
| title_full | Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials |
| title_short | Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials |
| title_sort | tocilizumab for covid 19 a systematic review and meta analysis of randomized controlled trials |
| topic | Tocilizumab COVID-19 meta-analysis interleukin 6 IL-6 inhibitor SARS CoV-2 |
| url | https://www.monaldi-archives.org/index.php/macd/article/view/2136 |
| work_keys_str_mv | AT tarunkrishnaboppana tocilizumabforcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT saurabhmittal tocilizumabforcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT karanmadan tocilizumabforcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT anantmohan tocilizumabforcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT vijayhadda tocilizumabforcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT randeepguleria tocilizumabforcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials |